Published in Int J Colorectal Dis on April 01, 1999
At the crossroads of inflammation and tumorigenesis. J Exp Med (1999) 1.61
Phosphoinositide 3-kinase signaling mediates beta-catenin activation in intestinal epithelial stem and progenitor cells in colitis. Gastroenterology (2010) 1.57
Increased proliferation and apoptosis of colonic epithelial cells in dextran sulfate sodium-induced colitis in rats. Dig Dis Sci (2002) 1.28
Endoscopic and pathological aspects of colitis-associated dysplasia. Nat Rev Gastroenterol Hepatol (2009) 0.83
Immunohistochemical expression of cyclin D1, cyclin E, p21/waf1 and p27/kip1 in inflammatory bowel disease: correlation with other cell-cycle-related proteins (Rb, p53, ki-67 and PCNA) and clinicopathological features. Int J Colorectal Dis (2004) 0.81
Early p53 mutations in nondysplastic Barrett's tissue detected by the restriction site mutation (RSM) methodology. Br J Cancer (2003) 0.78
Diagnostic yield of endomicroscopy for dysplasia in primary sclerosing cholangitis associated inflammatory bowel disease: a feasibility study. Endosc Int Open (2016) 0.77
Functional genomics in gastroenterology. Gut (2000) 0.76
Toll-like receptor 4 signaling integrates intestinal inflammation with tumorigenesis: lessons from the murine model of colitis-associated cancer. Cancers (Basel) (2011) 0.75
A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut (2000) 3.69
Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society. Semin Oncol (1991) 3.15
Primary sclerosing cholangitis in ulcerative colitis--a risk factor for the development of dysplasia and DNA aneuploidy? Gastroenterology (1992) 2.61
A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med (1994) 2.58
Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology (1995) 2.44
Cytomegalovirus infection of human blood cells. J Infect Dis (1984) 2.38
Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis. Acta Paediatr Scand (1991) 2.29
Citrullination is an inflammation-dependent process. Ann Rheum Dis (2006) 2.25
Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. Gut (1998) 2.14
Microscopic colitis syndrome. Gut (1995) 1.98
Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut (2004) 1.87
Cancer surveillance of patients with longstanding ulcerative colitis: a clinical, endoscopical, and histological study. Gut (1986) 1.87
Colorectal cancer rates among first-degree relatives of patients with inflammatory bowel disease: a population-based cohort study. Lancet (2001) 1.72
Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut (2005) 1.70
Increased risk of cancer in ulcerative colitis: a population-based cohort study. Am J Gastroenterol (1999) 1.65
Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology (2001) 1.63
Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. Leuk Res (1997) 1.55
Down-regulation of interferon-gamma parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study. Int J Colorectal Dis (2006) 1.53
Incidence of Crohn's disease in Stockholm County 1955-1989. Gut (1997) 1.52
Occupational exposure to electromagnetic fields in relation to leukemia and brain tumors: a case-control study in Sweden. Cancer Causes Control (1993) 1.51
A controlled randomized trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Scand J Gastroenterol (1987) 1.47
Myelodysplastic syndrome following epipodophyllotoxin therapy in familial hemophagocytic lymphohistiocytosis. Pediatr Hematol Oncol (1993) 1.43
Colonoscopic surveillance in long-standing total ulcerative colitis--a 15-year follow-up study. Gastroenterology (1990) 1.43
[Great risk of cancer in ulcerative colitis. Colonoscopic monitoring is recommended]. Lakartidningen (1995) 1.40
Pouchitis following pelvic pouch operation for ulcerative colitis. Incidence, cumulative risk, and risk factors. Dis Colon Rectum (1996) 1.40
The risk of colorectal cancer in ulcerative colitis. An epidemiologic study. Scand J Gastroenterol (1987) 1.37
An international survey of the use and attitudes regarding alternative medicine by patients with inflammatory bowel disease. Am J Gastroenterol (1999) 1.23
Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol (1997) 1.22
Histopathology and immunohistology of HTLV-III/LAV related lymphadenopathy and AIDS. Acta Pathol Microbiol Immunol Scand A (1987) 1.21
Clinical course of colorectal Crohn's disease: a 35-year follow-up study of 507 patients. Gastroenterology (1998) 1.20
Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group. Gastroenterology (1999) 1.17
A predictive model for the clinical response to low dose ara-C: a study of 102 patients with myelodysplastic syndromes or acute leukaemia. Br J Haematol (1992) 1.16
Insulin-induced GLUT4 translocation to the plasma membrane is blunted in large compared with small primary fat cells isolated from the same individual. Diabetologia (2007) 1.11
Prognostic information from cytogenetic analysis in chronic B-lymphocytic leukemia and leukemic immunocytoma. Blood (1985) 1.08
Elevated low density lipoprotein receptor activity in leukemic cells with monocytic differentiation. Blood (1984) 1.06
KBM-7, a human myeloid leukemia cell line with double Philadelphia chromosomes lacking normal c-ABL and BCR transcripts. Leukemia (1995) 1.05
Neoplastic transformation of the pelvic pouch mucosa in patients with ulcerative colitis. Gastroenterology (1997) 1.03
Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol (1998) 0.96
Subclinical time span of inflammatory bowel disease in patients with primary sclerosing cholangitis. Dis Colon Rectum (1995) 0.96
Leukocyte migration in acute colonic inflammatory bowel disease: comparison of histological assessment and Tc-99m-HMPAO labeled leukocyte scan. Am J Gastroenterol (1997) 0.94
Dynamics of mucosal permeability and inflammation in collagenous colitis before, during, and after loop ileostomy. Gut (2005) 0.93
Flow cytometric DNA analysis in longstanding ulcerative colitis: a method of prediction of dysplasia and carcinoma development? Gut (1987) 0.93
Laminin-5 gamma 2 chain expression correlates with unfavorable prognosis in colon carcinomas. Anal Cell Pathol (2001) 0.91
Long-term results of ileorectal anastomosis in ulcerative colitis in Stockholm County. Dis Colon Rectum (1990) 0.91
Low molecular weight heparin as adjuvant therapy in active ulcerative colitis. Aliment Pharmacol Ther (1999) 0.91
The prevalence and clinical significance of alpha 1-antitrypsin deficiency (PiZ) and ANCA specificities (proteinase 3, BPI) in patients with ulcerative colitis. Inflamm Bowel Dis (1999) 0.90
Long-term histomorphological surveillance of the pelvic ileal pouch: dysplasia develops in a subgroup of patients. Gastroenterology (1995) 0.89
Preoperative short-term radiotherapy in rectal carcinoma. A preliminary report of a prospective randomized study. Cancer (1985) 0.88
Undifferentiated pelvic adenocarcinomas: diagnostic potential of protein profiling and multivariate analysis. Int J Colorectal Dis (2008) 0.88
DNA aneuploidy in ulcerative colitis: reproducibility, topographic distribution, and relation to dysplasia. Gastroenterology (1992) 0.88
Kala-azar in a one-year-old Swedish child. Diagnostic difficulties because of active hemophagocytosis. Acta Paediatr (1993) 0.87
Ropivacaine gel in active distal ulcerative colitis and proctitis -- a pharmacokinetic and exploratory clinical study. Aliment Pharmacol Ther (1996) 0.87
Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up. Ann Oncol (2007) 0.86
Effect of budesonide enema on remission and relapse rate in distal ulcerative colitis and proctitis. Scand J Gastroenterol (2002) 0.86
Laminin 5 gamma 2 chain expression: a marker of early invasiveness in colorectal adenomas. Mol Pathol (2003) 0.86
Tranexamic acid in massive haemorrhage from the upper gastrointestinal tract: a double-blind study. Scand J Gastroenterol (1979) 0.85
High-resolution computed tomography in the diagnosis of miliary tuberculosis. Chest (1992) 0.85
Myocardial rupture with cardiac tamponade as a lethal early manifestation of acute myeloblastic leukemia. Cancer (1982) 0.83
A 10-year survey of inflammatory bowel diseases-drug therapy, costs and adverse reactions. Aliment Pharmacol Ther (2001) 0.83
Gastroesophageal reflux in healthy subjects. Significance of endoscopic findings, histology, age, and sex. Scand J Gastroenterol (1999) 0.83
Clinical trial: the safety and short-term efficacy of recombinant cholera toxin B subunit in the treatment of active Crohn's disease. Aliment Pharmacol Ther (2009) 0.83
Acetazolamide-associated aplastic anaemia. J Intern Med (1990) 0.83
Evidence for immunosurveillance in intestinal premalignant lesions. Scand J Immunol (2010) 0.83
KBM-3, an in vitro model of human acute myelomonocytic leukemia. Exp Hematol (1992) 0.82
Response to interferon therapy in patients with multiple myeloma correlates with expression of the Bcl-2 oncoprotein. Int J Cancer (1995) 0.82
Diagnoses in patients with severe pancytopenia suspected of having aplastic anemia. Eur J Haematol (1990) 0.82
Hyperplastic foveolar gastropathies and hyperplastic foveolar gastritis. APMIS (1997) 0.82
Heparin protects against skin flap necrosis: relationship to neutrophil recruitment and anti-coagulant activity. Inflamm Res (2004) 0.82
Antibody producing human-human hybridomas. II. Derivation and characterization of an antibody specific for human leukemia cells. J Exp Med (1984) 0.81
Carcinoma and DNA aneuploidy in Crohn's colitis--a histological and flow cytometric study. Gut (1991) 0.81
Treatment of myelodysplastic syndromes with recombinant human erythropoietin. Eur J Haematol (1991) 0.80
A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis. Scand J Gastroenterol (1992) 0.80
Glucocorticoid receptor concentrations and terminal transferase activity as indicators of prognosis in acute non-lymphocytic leukaemia. Br Med J (Clin Res Ed) (1981) 0.80
Acute leukaemia in a defined geographic area--incidence, clinical history and prognosis. Scand J Haematol (1984) 0.80
Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study. Am J Gastroenterol (1995) 0.80
DNA image cytometry and the expression of proliferative markers (proliferating cell nuclear antigen and Ki67) in non-Hodgkin's lymphomas. Mod Pathol (1995) 0.80
A study of the reproducibility of the diagnostic criteria for acute leukaemia. Scand J Haematol (1983) 0.79
Glucocorticoid receptor mRNA in patients with ulcerative colitis: a study of responders and nonresponders to glucocorticosteroid therapy. Inflamm Bowel Dis (2001) 0.78
Reversal of myelofibrosis by hydroxyurea. Eur J Haematol (1990) 0.78
[Cancer in the ventricular remnant following resection for benign ulcer disease]. Lakartidningen (1981) 0.78
Instant technetium 99m hexamethyl propylenamine oxime-labeled leukocyte scan compared with colonoscopy in early assessment of disease extent and activity in acute colitis. Dis Colon Rectum (1996) 0.78
Colorectal cancer in colonic Crohn's disease--high frequency of DNA-aneuploidy. Anticancer Res (2005) 0.78
Bone marrow transplantation in two children with congenital amegakaryocytic thrombocytopenia. Bone Marrow Transplant (1995) 0.78
Allopurinol in addition to 5-aminosalicylic acid based drugs for the maintenance treatment of ulcerative colitis. Aliment Pharmacol Ther (2000) 0.77
Spontaneous and cytokine-induced thrombocytopenia in myelodysplastic syndromes: serum thrombopoietin levels and bone marrow morphology. Scandinavian MDS Group, Sweden and Norway. Br J Haematol (1999) 0.77
Low-dose ara-C in myelodysplastic syndromes (MDS) and acute leukemia following MDS: proposal for a predictive model. Leuk Lymphoma (1994) 0.77
Immunodeficiency and prognosis in patients with non-Hodgkin's lymphomas. Acta Radiol Oncol (1985) 0.77
Effects of retinoic acid, 1,25-dihydroxyvitamin D3, cytosine arabinoside and alpha-interferon on bone marrow cells from patients with myelodysplastic syndromes. Leuk Res (1989) 0.77
Prognostic significance of proliferative and apoptotic fractions in low grade follicle center cell-derived non-Hodgkin's lymphomas. Cancer (1996) 0.77
Sialyl-Tn antigen as a marker of colon cancer risk in ulcerative colitis: relation to dysplasia and DNA aneuploidy. Gastroenterology (1998) 0.77
Mutagen exposures and chromosome 3 aberrations in acute myelocytic leukemia. Leukemia (2000) 0.77
Blocking of MHC class I antigens on leukemic B-cells enhances their conjugate formation with cytotoxic lymphocytes and their susceptibility to lysis. Leuk Lymphoma (1998) 0.77
DNA content and expression of PCNA and p53 in Hodgkin's disease and Hodgkin's-like B-cell lymphoma. APMIS (1994) 0.77